RRM2B Antibody

• The expression of p53R2 has been closely linked to the development and progression of lung sarcomatoid carcinoma. PMID: 29246119
• p53R2 protein is overexpressed in early-stage cervical cancer, suggesting unconventional oncogenic functions of p53R2. PMID: 28841361
• High levels of RRM2B expression have been associated with various neoplasms. PMID: 27004405
• Studies have investigated the expression of ribonucleotide reductase (RR) subunit p53R2 in nasopharyngeal carcinoma and its potential role in prognosis. PMID: 29237424
• The RRM1/RRM2B enzyme complex can maintain its activity in hypoxic environments. This makes it a preferred enzyme over RRM1/RRM2 to sustain ongoing replication and minimize DNA damage accumulation in hypoxic cells. PMID: 28416140
• Research has unveiled a novel role for E2F1 in regulating p53R2 expression during the DNA damage response. PMID: 25312903
• Studies have analyzed the caspase-dependent degradation of the human R2 and p53R2 small subunits. PMID: 25878246
• In a Turkish population, the p53R2 genotype distributions between head and neck squamous epithelial cell cancer patients and control groups did not show statistically significant differences. PMID: 24861915
• Data indicate that forkhead transcription factors F OXO3 directly bind to and activate the promoter of the ribonucleotide reductase subunit RRM2B, leading to increased expression of RRM2B at both RNA and protein levels. PMID: 24947616
• Research has failed to find evidence supporting the hypothesis that aberrations in RRM1 or RRM2B, either individually or in combination, are associated with altered clinical outcomes following chemotherapy. PMID: 24215511
• Ribonucleotide reductase M2B inhibits cell migration and spreading through the early growth response protein 1-mediated phosphatase and tensin homolog/Akt1 pathway in hepatocellular carcinoma. PMID: 24214128
• RRM2B expression may differentiate cervical cancer phenotypes and predict radiochemotherapy outcomes. PMID: 23552804
• RRM2B is significantly induced in a p53-dependent manner during senescence and exhibits higher expression levels in senescent precancerous human prostatic intraepithelial neoplasm lesions compared to adjacent normal prostate glands. PMID: 23139867
• p53R2 may regulate matrix synthesis through Akt phosphorylation during chondrocyte mechanotransduction. Down-regulation of p53R2 could potentially serve as a novel therapeutic approach for osteoarthritis treatment. PMID: 22954457
• p53R2 is directly regulated by p53 and also by a MEK2 (ERK kinase 2/MAP kinase kinase 2)-dependent pathway. PMID: 22895183
• p53R2 is proposed as a therapeutic target to enhance the effectiveness of chemotherapy in patients with p53R2-positive melanoma. PMID: 22902076
• Research suggests that p53R2 plays a role in the mechanisms of action of both Clofarabine and decitabine. PMID: 22884950
• In non-transformed cells, protein p53R2 is essential for the maintenance of mitochondrial DNA and for optimal DNA repair following ultraviolet damage, particularly during quiescence. PMID: 22847445
• Evidence suggests that disease pathogenesis may be caused by defective RNR assembly. PMID: 21378381
• Increased expression of p53R2 may predict resistance to gemcitabine, and upregulated RNR activity might influence gemcitabine resistance in cholangiocarcinoma cells. PMID: 21451941
• p53R2 might suppress cancer cell proliferation and play critical roles not only in DNA damage repair but also in the proliferation of cancer cells. PMID: 21216934
• p53R2 expression seems to be more crucial than that of hRRM2 in the prognosis of early-stage lung cancer. PMID: 21965764
• Research provides functional evidence that mitochondria is one of the p53R2-targeted organelles. This suggests an unexpected function of p53R2 beyond its known ribonucleotide reductase function in dNTP synthesis, namely, in mitochondrial homeostatic control. PMID: 21640705
• Adult-onset progressive external ophthalmoplegia due to RRM2B mutations is associated with a benign myopathic phenotype and is characterized by muscle-restricted, mitochondrial DNA deletions. PMID: 21646632
• Loss of p53R2 affects ribonucleotide reduction only in resting cells and leads to a decrease in dNTP catabolism by substrate cycles, counteracting the loss of anabolic activity. PMID: 21297166
• A study correlates the distinct catalytic mechanisms of the small subunits hp53R2 and hRRM2 with a hydrogen-bonding network. PMID: 20484015
• p53R2-dependent DNA synthesis is crucial for cell survival by repairing damaged DNA. PMID: 11719458
• Expression of p53R2, a newly identified p53 target, has been observed in oral normal epithelium, epithelial dysplasia, and squamous cell carcinoma. PMID: 12565178
• Wild-type p53 regulates human ribonucleotide reductase through protein-protein interactions with both p53R2 and hRRM2 subunits. PMID: 12615712
• UV-induced activation of p53R2 transcription and binding of p53R2 to hRRM1 to form the RR holoenzyme are impaired in the p53-mutant cell line PC3. PMID: 14583450
• Four regulatory-region variants were found, including three single nucleotide polymorphisms (SNPs) (nt 1 789 C/G, nt 1 928 A/G, 1 933 T/C), and one 20 bp insertion that replaced a ATTTT between nt 1831 and 1835. PMID: 16127747
• Researchers developed a p53R2-dependent luciferase reporter gene assay and demonstrated dose-dependent luminescence induced by adriamycin in two human cell lines expressing wild-type p53, MCF-7 and HepG2. PMID: 16236544
• RRM2 and p53R2 subunits share the same binding site on RRM1. PMID: 16376858
• Expressions of p53 and p53R2 proteins could be useful in determining tumor characteristics, including prognosis, in patients with esophageal squamous cell carcinoma. PMID: 16778101
• The catalytic properties of p53R2 have been assessed. PMID: 16846634
• Ectopic expression of human papillomavirus 16 E6 impaired p53R2 induction after DNA damage in human fibroblasts. PMID: 16872707
• Mutation of RRM2B has been linked to mitochondrial diseases. PMID: 17486094
• p53R2 expression is reduced after X-ray irradiation following the transfection of p53R2 siRNA in esophageal squamous cell carcinoma. This suggests a potential improvement in the efficacy of radiotherapy. PMID: 17671702
• Research indicates a protective function of the p53R2 ribonucleotide reductase subunit in preventing or repairing NO-mediated genotoxic injury. PMID: 18474260
• Sequencing the RRM2B gene revealed three missense mutations and two single nucleotide deletions in exons 6, 8, and 9, confirming the significance of RRM2B mutations as causes of myelodysplastic syndromes (MDS). PMID: 18504129
• Studies have analyzed the effects of p53R2 silencing on DNA damage in LNCaP cells. PMID: 18505925
• p53R2 constitutes a potential target for anticancer drugs as well as a diagnostic marker in cancer. PMID: 18760875
• The redox property, structure, and function of hRRM2 and p53R2 have been studied. PMID: 19082948
• A report describes two brothers, both deceased in infancy, with severe depletion of mitochondrial DNA (mtDNA) in muscle tissue. A novel missense mutation in the RRM2B gene, encoding the p53R2 subunit, was identified. PMID: 19138848
• A heterozygous truncating mutation in RRM2B causes autosomal-dominant progressive external ophthalmoplegia with multiple mtDNA deletions. PMID: 19664747
• Research expands the clinical spectrum of impaired RIR2B function. PMID: 19667227
• The X-ray crystal structure of human p53R2 is determined to 2.6 A, in which monomers A and B exhibit mono- and binuclear iron occupancy, respectively. Sequence-structure-function correlations that differentiate p53R2 and RRM2 are revealed. PMID: 19728742

HGNC: 17296

OMIM: 604712

KEGG: hsa:50484

STRING: 9606.ENSP00000251810

UniGene: Hs.512592